{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:07Z","timestamp":1792602907521,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glioblastoma (GBM) is the most frequent and lethal brain tumor, whose therapeutic outcome - only partially effective with current schemes - places this disease among the unmet medical needs, and effective therapeutic approaches are urgently required. In our attempts to identify repositionable drugs in glioblastoma therapy, we identified the neuroleptic drug chlorpromazine (CPZ) as a very promising compound. Here we aimed to further unveil the mode of action of this drug. We performed a supervised recognition of the signal transduction pathways potentially influenced by CPZ via Reverse-Phase Protein microArrays (RPPA) and carried out an Activity-Based Protein Profiling (ABPP) followed by Mass Spectrometry (MS) analysis to possibly identify cellular factors targeted by the drug. Indeed, the glycolytic enzyme PKM2 was identified as one of the major targets of CPZ. Furthermore, using the Seahorse platform, we analyzed the bioenergetics changes induced by the drug. Consistent with the ability of CPZ to target PKM2, we detected relevant changes in GBM energy metabolism, possibly attributable to the drug\u2019s ability to inhibit the oncogenic properties of PKM2. RPE-1 non-cancer neuroepithelial cells appeared less responsive to the drug. PKM2 silencing reduced the effects of CPZ. 3D modeling showed that CPZ interacts with PKM2 tetramer in the same region involved in binding other known activators. The effect of CPZ can be epitomized as an inhibition of the Warburg effect and thus malignancy in GBM cells, while sparing RPE-1 cells. These preclinical data enforce the rationale that allowed us to investigate the role of CPZ in GBM treatment in a recent multicenter Phase II clinical trial.<\/jats:p>","DOI":"10.1038\/s41419-023-06353-3","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T13:02:34Z","timestamp":1702472554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Chlorpromazine affects glioblastoma bioenergetics by interfering with pyruvate kinase M2"],"prefix":"10.1038","volume":"14","author":[{"given":"Claudia","family":"Abbruzzese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Matteoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5477-3752","authenticated-orcid":false,"given":"Paola","family":"Matarrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0262-842X","authenticated-orcid":false,"given":"Michele","family":"Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Iessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymone","family":"Gurtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ricci-Vitiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6330-6053","authenticated-orcid":false,"given":"Alfredo","family":"Budillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-8605","authenticated-orcid":false,"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9445-442X","authenticated-orcid":false,"given":"Marco G.","family":"Paggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"6353_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ncl.2016.06.014","volume":"34","author":"KA McNeill","year":"2016","unstructured":"McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34:981\u201398.","journal-title":"Neurol Clin"},{"key":"6353_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl J Med. 2005;352:987\u201396.","journal-title":"N. Engl J Med"},{"key":"6353_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc1121","volume":"3","author":"JS Rao","year":"2003","unstructured":"Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003;3:489\u2013501.","journal-title":"Nat Rev Cancer"},{"key":"6353_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/ana.22036","volume":"68","author":"M Glas","year":"2010","unstructured":"Glas M, Rath BH, Simon M, Reinartz R, Schramme A, Trageser D, et al. Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol. 2010;68:264\u20139.","journal-title":"Ann Neurol"},{"key":"6353_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature23666","volume":"549","author":"X Lan","year":"2017","unstructured":"Lan X, Jorg DJ, Cavalli FMG, Richards LM, Nguyen LV, Vanner RJ, et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature. 2017;549:227\u201332.","journal-title":"Nature"},{"key":"6353_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1101\/gad.324301.119","volume":"33","author":"RC Gimple","year":"2019","unstructured":"Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev. 2019;33:591\u2013609.","journal-title":"Genes Dev"},{"key":"6353_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17186-5","volume":"11","author":"CP Couturier","year":"2020","unstructured":"Couturier CP, Ayyadhury S, Le PU, Nadaf J, Monlong J, Riva G, et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat Commun. 2020;11:3406.","journal-title":"Nat Commun"},{"key":"6353_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature16071","volume":"528","author":"M Osswald","year":"2015","unstructured":"Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, et al. Brain tumour cells interconnect to a functional and resistant network. Nature. 2015;528:93\u20138.","journal-title":"Nature"},{"key":"6353_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13046-017-0642-x","volume":"36","author":"C Abbruzzese","year":"2017","unstructured":"Abbruzzese C, Matteoni S, Signore M, Cardone L, Nath K, Glickson JD, et al. Drug repurposing for the treatment of glioblastoma multiforme. J Exp Clin Cancer Res. 2017;36:169.","journal-title":"J Exp Clin Cancer Res"},{"key":"6353_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/cells11020263","volume":"11","author":"M Persico","year":"2022","unstructured":"Persico M, Abbruzzese C, Matteoni S, Matarrese P, Campana AM, Villani V, et al. Tackling the behavior of cancer cells: molecular bases for repurposing antipsychotic drugs in the treatment of glioblastoma. Cells. 2022;11:263.","journal-title":"Cells"},{"key":"6353_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41568-022-00475-0","volume":"22","author":"V Venkataramani","year":"2022","unstructured":"Venkataramani V, Schneider M, Giordano FA, Kuner T, Wick W, Herrlinger U, et al. Disconnecting multicellular networks in brain tumours. Nat Rev Cancer. 2022;22:481\u201391.","journal-title":"Nat Rev Cancer"},{"key":"6353_CR12","doi-asserted-by":"publisher","first-page":"635472","DOI":"10.3389\/fonc.2021.635472","volume":"11","author":"S Matteoni","year":"2021","unstructured":"Matteoni S, Matarrese P, Ascione B, Buccarelli M, Ricci-Vitiani L, Pallini R, et al. Anticancer properties of the antipsychotic drug chlorpromazine and its synergism with temozolomide in restraining human glioblastoma proliferation In Vitro. Front Oncol. 2021;11:635472.","journal-title":"Front Oncol"},{"key":"6353_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13046-021-02144-w","volume":"40","author":"S Matteoni","year":"2021","unstructured":"Matteoni S, Matarrese P, Ascione B, Ricci-Vitiani L, Pallini R, Villani V, et al. Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response. J Exp Clin Cancer Res. 2021;40:347.","journal-title":"J Exp Clin Cancer Res"},{"key":"6353_CR14","unstructured":"World Health Organization Model List of Essential Medicines, 22nd List. Geneva: World Health Organization; 2021."},{"key":"6353_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"JM Beaulieu","year":"2011","unstructured":"Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharm Rev. 2011;63:182\u2013217.","journal-title":"Pharm Rev"},{"key":"6353_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.brainres.2017.01.028","volume":"1660","author":"OI Barygin","year":"2017","unstructured":"Barygin OI, Nagaeva EI, Tikhonov DB, Belinskaya DA, Vanchakova NP, Shestakova NN. Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics. Brain Res. 2017;1660:58\u201366.","journal-title":"Brain Res"},{"key":"6353_CR17","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s42255-021-00424-5","volume":"3","author":"EK Wiese","year":"2021","unstructured":"Wiese EK, Hitosugi S, Loa ST, Sreedhar A, Andres-Beck LG, Kurmi K, et al. Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effect. Nat Metab. 2021;3:954\u201368.","journal-title":"Nat Metab"},{"key":"6353_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cmet.2014.12.005","volume":"21","author":"EM Palsson-McDermott","year":"2015","unstructured":"Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, et al. Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015;21:65\u201380.","journal-title":"Cell Metab"},{"key":"6353_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12431","volume":"7","author":"J Liang","year":"2016","unstructured":"Liang J, Cao R, Zhang Y, Xia Y, Zheng Y, Li X, et al. PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis. Nat Commun. 2016;7:12431.","journal-title":"Nat Commun"},{"key":"6353_CR20","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1073\/pnas.1014769108","volume":"108","author":"Q Sun","year":"2011","unstructured":"Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA. 2011;108:4129\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6353_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40170-021-00239-8","volume":"9","author":"F Almouhanna","year":"2021","unstructured":"Almouhanna F, Blagojevic B, Can S, Ghanem A, Wolfl S. Pharmacological activation of pyruvate kinase M2 reprograms glycolysis leading to TXNIP depletion and AMPK activation in breast cancer cells. Cancer Metab. 2021;9:5.","journal-title":"Cancer Metab"},{"key":"6353_CR22","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.molcel.2012.01.001","volume":"45","author":"X Gao","year":"2012","unstructured":"Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell. 2012;45:598\u2013609.","journal-title":"Mol Cell"},{"key":"6353_CR23","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/0008-5472.CAN-17-2726","volume":"78","author":"Z Zhou","year":"2018","unstructured":"Zhou Z, Li M, Zhang L, Zhao H, Sahin O, Chen J, et al. Oncogenic Kinase-Induced PKM2 Tyrosine 105 phosphorylation converts nononcogenic PKM2 to a tumor promoter and induces cancer stem-like cells. Cancer Res. 2018;78:2248\u201361.","journal-title":"Cancer Res"},{"key":"6353_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","volume":"150","author":"W Yang","year":"2012","unstructured":"Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012;150:685\u201396.","journal-title":"Cell"},{"key":"6353_CR25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/ncb2629","volume":"14","author":"W Yang","year":"2012","unstructured":"Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, et al. ERK1\/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat cell Biol. 2012;14:1295\u2013304.","journal-title":"Nat cell Biol"},{"key":"6353_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature10598","volume":"480","author":"W Yang","year":"2011","unstructured":"Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 2011;480:118\u201322.","journal-title":"Nature"},{"key":"6353_CR27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736\u201346.","journal-title":"Nat Rev Cancer"},{"key":"6353_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.canlet.2014.01.031","volume":"356","author":"N Wong","year":"2015","unstructured":"Wong N, Ojo D, Yan J, Tang D. PKM2 contributes to cancer metabolism. Cancer Lett. 2015;356:184\u201391.","journal-title":"Cancer Lett"},{"key":"6353_CR29","doi-asserted-by":"publisher","first-page":"17425","DOI":"10.1074\/jbc.RA120.015800","volume":"295","author":"S Nandi","year":"2020","unstructured":"Nandi S, Razzaghi M, Srivastava D, Dey M. Structural basis for allosteric regulation of pyruvate kinase M2 by phosphorylation and acetylation. J Biol Chem. 2020;295:17425\u201340.","journal-title":"J Biol Chem"},{"key":"6353_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29085-y","volume":"13","author":"C Sebastian","year":"2022","unstructured":"Sebastian C, Ferrer C, Serra M, Choi JE, Ducano N, Mira A, et al. A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestine. Nat Commun. 2022;13:1503.","journal-title":"Nat Commun"},{"key":"6353_CR31","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/carcin\/bgt169","volume":"34","author":"SY Shin","year":"2013","unstructured":"Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y, et al. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt\/mTOR pathway in human U-87MG glioma cells. Carcinogenesis. 2013;34:2080\u20139.","journal-title":"Carcinogenesis"},{"key":"6353_CR32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc.2017.77","volume":"17","author":"C Corbet","year":"2017","unstructured":"Corbet C, Feron O. Tumour acidosis: from the passenger to the driver\u2019s seat. Nat Rev Cancer. 2017;17:577\u201393.","journal-title":"Nat Rev Cancer"},{"key":"6353_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nchembio.1060","volume":"8","author":"D Anastasiou","year":"2012","unstructured":"Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8:839\u201347.","journal-title":"Nat Chem Biol"},{"key":"6353_CR34","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.bcp.2009.12.003","volume":"79","author":"MG Vander Heiden","year":"2010","unstructured":"Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharm. 2010;79:1118\u201324.","journal-title":"Biochem Pharm"},{"key":"6353_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(72)92955-8","volume":"2","author":"LK Csatary","year":"1972","unstructured":"Csatary LK. Chlorpromazines and cancer. Lancet. 1972;2:338\u20139.","journal-title":"Lancet"},{"key":"6353_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/1758834016659791","volume":"8","author":"S Faraz","year":"2016","unstructured":"Faraz S, Pannullo S, Rosenblum M, Smith A, Wernicke AG. Long-term survival in a patient with glioblastoma on antipsychotic therapy for schizophrenia: a case report and literature review. Ther Adv Med Oncol. 2016;8:421\u20138.","journal-title":"Ther Adv Med Oncol"},{"key":"6353_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl J Med. 2005;352:997\u20131003.","journal-title":"N. Engl J Med"},{"key":"6353_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673\u201383.","journal-title":"Nat Rev Drug Discov"},{"key":"6353_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo N. Can you teach old drugs new tricks? Nature. 2016;534:314\u20136.","journal-title":"Nature"},{"key":"6353_CR40","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","volume":"20","author":"J Langedijk","year":"2015","unstructured":"Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20:1027\u201334.","journal-title":"Drug Discov Today"},{"key":"6353_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13046-019-1212-1","volume":"38","author":"S Matteoni","year":"2019","unstructured":"Matteoni S, Abbruzzese C, Matarrese P, De Luca G, Mileo AM, Miccadei S, et al. The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells. J Exp Clin Cancer Res. 2019;38:202.","journal-title":"J Exp Clin Cancer Res"},{"key":"6353_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03909-z","volume":"12","author":"M Signore","year":"2021","unstructured":"Signore M, Alfonsi R, Federici G, Nanni S, Addario A, Bertuccini L, et al. Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer. Cell Death Dis. 2021;12:636.","journal-title":"Cell Death Dis"},{"key":"6353_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.mcb.2022.04.004","volume":"171","author":"M Signore","year":"2022","unstructured":"Signore M, Manganelli V. Reverse Phase Protein Arrays in cancer stem cells. Methods Cell Biol. 2022;171:33\u201361.","journal-title":"Methods Cell Biol"},{"key":"6353_CR44","doi-asserted-by":"publisher","first-page":"22529","DOI":"10.1002\/jcp.28816","volume":"234","author":"C Abbruzzese","year":"2019","unstructured":"Abbruzzese C, Matteoni S, Persico M, Ascione B, Schenone S, Musumeci F, et al. The small molecule SI113 hinders epithelial-to-mesenchymal transition and subverts cytoskeletal organization in human cancer cells. J Cell Physiol. 2019;234:22529\u201342.","journal-title":"J Cell Physiol"},{"key":"6353_CR45","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785\u201391.","journal-title":"J Comput Chem"},{"key":"6353_CR46","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1016\/j.bmc.2017.05.004","volume":"25","author":"Y Matsui","year":"2017","unstructured":"Matsui Y, Yasumatsu I, Asahi T, Kitamura T, Kanai K, Ubukata O, et al. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator. Bioorg Med Chem. 2017;25:3540\u20136.","journal-title":"Bioorg Med Chem"},{"key":"6353_CR47","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51:2778\u201386.","journal-title":"J Chem Inf Model"},{"key":"6353_CR48","doi-asserted-by":"publisher","first-page":"W530","DOI":"10.1093\/nar\/gkab294","volume":"49","author":"MF Adasme","year":"2021","unstructured":"Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ, et al. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021;49:W530\u2013W4.","journal-title":"Nucleic Acids Res"},{"key":"6353_CR49","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1093\/bioinformatics\/btw514","volume":"32","author":"LC Xue","year":"2016","unstructured":"Xue LC, Rodrigues JP, Kastritis PL, Bonvin AM, Vangone A. PRODIGY: a web server for predicting the binding affinity of protein-protein complexes. Bioinformatics. 2016;32:3676\u20138.","journal-title":"Bioinformatics"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06353-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06353-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06353-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T14:04:20Z","timestamp":1702476260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06353-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6353"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06353-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"821"}}